PMID- 38400790
OWN - NLM
STAT- MEDLINE
DCOM- 20240408
LR  - 20240408
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 15
IP  - 10
DP  - 2024 Apr
TI  - Efficacy and safety of local ablative therapy for patients with NSCLC and 
      coexisting interstitial lung disease.
PG  - 778-787
LID - 10.1111/1759-7714.15258 [doi]
AB  - BACKGROUND: The effective therapeutic approach is still an unmet need for 
      patients diagnosed with both lung cancer and interstitial lung disease (ILD). 
      This is primarily due to the possible risk of ILD exacerbation caused by surgery 
      or radiotherapy. The current study aimed to investigate the efficacy and safety 
      of local ablative therapy (LAT) for this specific population. METHODS: 
      Consecutive patients with non-small cell lung cancer (NSCLC) and ILD who received 
      LAT between January 2018 and August 2022 were enrolled, and propensity score 
      matching (PSM) was utilized to match the non-ILD group. The primary endpoint was 
      recurrence-free survival (RFS), and secondary endpoints included overall survival 
      (OS), adverse events (AEs) and hospital length of stay (HLOS). RESULTS: The PSM 
      algorithm yielded matched pairs in the ILD group (n = 25) and non-ILD group 
      (n = 72) at a ratio of 1:3. There were no statistically significant differences 
      in RFS (median 16.4 vs. 18 months; HR = 1.452, p = 0.259) and OS (median: not 
      reached vs. 47.9 months; HR = 1.096, p = 0.884) between the two groups. 
      Meanwhile, no acute exacerbation of ILD was observed in the ILD group. However, 
      the incidence of pneumothorax, especially pneumothorax requiring chest tube 
      drainage, was significantly higher (36.0% vs. 11.2%, p = 0.005) among patients 
      with NSCLC and co-existing ILD, which resulted in longer HLOS (p = 0.045). 
      CONCLUSION: Although ILD was associated with a higher incidence of pneumothorax, 
      the efficacy of LAT for NSCLC patients with ILD was comparable to those without 
      ILD, suggesting that LAT might be a reliable and effective treatment option for 
      this population, particularly in the early stage.
CI  - (c) 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, 
      Ltd.
FAU - Shao, Chuchu
AU  - Shao C
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Zhi, Xinxin
AU  - Zhi X
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Mao, Shiqi
AU  - Mao S
AUID- ORCID: 0000-0001-9596-6622
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Wu, Leilei
AU  - Wu L
AD  - Department of Radiology, Shanghai Pulmonary Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Yu, Jia
AU  - Yu J
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Yang, Shuo
AU  - Yang S
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Wang, Wanying
AU  - Wang W
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Jia, Keyi
AU  - Jia K
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Luo, Libo
AU  - Luo L
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Liu, Xinyu
AU  - Liu X
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Jiang, Tao
AU  - Jiang T
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Zhou, Fei
AU  - Zhou F
AUID- ORCID: 0000-0002-5865-0052
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Chen, Bin
AU  - Chen B
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Gao, Guanghui
AU  - Gao G
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Shi, Jingyun
AU  - Shi J
AD  - Department of Imaging, Shanghai Pulmonary Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Chen, Xiaoxia
AU  - Chen X
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Wu, Fengying
AU  - Wu F
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Ren, Shengxiang
AU  - Ren S
AUID- ORCID: 0000-0001-8767-9850
AD  - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
LA  - eng
GR  - FKLY20008/Clinical Research Foundation of Shanghai Pulmonary Hospital/
GR  - 21XD1423200/Science and Technology Commission of Shanghai Municipality/
GR  - 81972167/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20240224
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/complications/surgery/drug therapy
MH  - *Lung Neoplasms/complications/surgery/drug therapy
MH  - *Pneumothorax/complications
MH  - *Lung Diseases, Interstitial/complications/surgery/drug therapy
MH  - Treatment Outcome
MH  - Retrospective Studies
PMC - PMC10995702
OTO - NOTNLM
OT  - ILD
OT  - NSCLC
OT  - adverse event
OT  - efficacy
OT  - local ablative therapy
COIS- The authors declare no conflicts of interest.
EDAT- 2024/02/24 21:42
MHDA- 2024/04/08 06:44
PMCR- 2024/02/24
CRDT- 2024/02/24 09:53
PHST- 2024/02/02 00:00 [revised]
PHST- 2023/12/31 00:00 [received]
PHST- 2024/02/06 00:00 [accepted]
PHST- 2024/04/08 06:44 [medline]
PHST- 2024/02/24 21:42 [pubmed]
PHST- 2024/02/24 09:53 [entrez]
PHST- 2024/02/24 00:00 [pmc-release]
AID - TCA15258 [pii]
AID - 10.1111/1759-7714.15258 [doi]
PST - ppublish
SO  - Thorac Cancer. 2024 Apr;15(10):778-787. doi: 10.1111/1759-7714.15258. Epub 2024 
      Feb 24.